Kangyuan Pharmaceutical (600557.SH): Qihuangzhengqi granules approved for clinical trials

Zhitong Finance App News, Kangyuan Pharmaceutical (600557.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” for Qihuangzhengqi granules issued by the State Drug Administration, agreeing to carry out clinical trials of this product for cancer-induced fatigue. Qihuang Zhengqi granules are clinical empirical formulations formed under the theoretical guidance of traditional Chinese medicine. They have the effect of nourishing qi, nourishing blood, and correcting deficiencies.

According to reports, major preclinical pharmacodynamic studies have shown that Qihuangzhengqi granules have significant therapeutic effects on cancer-induced fatigue processes caused by murine non-small cell lung cancer cell LLC transplantation, mainly by enhancing endurance in model animals, inhibiting lactic acid accumulation and glycogen depletion in tumor-carrying animals, and improving the progression of death caused by cachexia; paclitaxel treatment has significant therapeutic effects on breast cancer-related cancer-related exhaustion processes, mainly by enhancing endurance and motor function in model animal organisms and inhibiting lactate accumulation in animal models and glycogen depletion. Toxicological study results showed that there were no serious adverse reactions in animals tested for single dose or repeated administration of Qihuangzhengqi granules, which were well tolerated and had good safety.